Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Overview
GIST is a relatively rare type of cancer. It originates in the "pacemakers" cells or named the interstitial cells of Cajal (ICCs) which locate in the wall of the GI tract. Most GIST tumors start from the stomach, but they may occur anywhere along the digestive tract from the esophagus, small intestine, rectum, colon, to the anus. More than half of all GIST arises in the stomach, while about one fourth develops in the small intestine. GIST is usually diagnosed in people older than 50, and slightly more cases in men versus women. Researches reveal that most GIST patients have a mutated c-kit gene, but the exact reason that the mutation causes this disease is still not completely clear.
Signs, symptoms and treatments
Many GIST patients with small tumor display no symptom, while pain or discomfort is usually to be the representative symptom on patient with tumor in larger size and/or at aggressive stage. Other symptoms such as vomiting, diarrhea, fatigue, loss of appetite, vomiting of blood and weight loss are also common in clinical reports. The primary option for treating early-stage GIST is still surgery, however, the radiation therapy can't show a satisfied prognosis. Therefore, unlike other common digestive tract cancers, GIST requires a more specially individualized treatment programme.
Loading...
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
